The Brain Reward Cascade (BRC) is an interaction of neurotransmitters and their respective genes to control the amount of dopamine released within the brain. Any variations within this pathway, whether genetic or environmental (epigenetic), may result in addictive behaviors as well as altered pain tolerance. While there are many studies claiming a genetic association with addiction and other behavioral infractions, defined as Reward Deficiency Syndrome (RDS), not all are scientifically accurate and in some case just wrong. Albeit our bias, we discuss herein the facts and fictions behind molecular genetic testing in RDS (including pain and addiction) and the significance behind the development of the Genetic Addiction Risk Score (GARSPREDX™), the first test to accurately predict one’s genetic risk for RDS.
 Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam
H, Reed L, Magenis RE, Civelli O: The human dopamine D2
receptor gene is located on chromosome 11 at q22-q23 and
identifies a TaqI RFLP. Am J Hum Genet 1989, 45(5): 778-785.
 Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T,
Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB: Allelic
association of human dopamine D2 receptor gene in
alcoholism. JAMA 1990, 263(15): 2055-2060.
 Conneally PM: Association between the D2 dopamine receptor
gene and alcoholism. A continuing controversy. Arch Gen
Psychiatry 1991, 48(8): 757-759.
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.